VYGR
Closed
Voyager Therapeutics Inc
6.13
-0.21 (-3.31%)
Last Update: 06 Sep 2024 23:00:00
Yesterday: 6.34
Day's Range: 5.97 - 6.37
Send
sign up or login to leave a comment!
When Written:
7.98
Voyager Therapeutics Inc. is a clinical-stage gene therapy company that is focused on developing treatments for severe neurological diseases. The company is headquartered in Cambridge, Massachusetts, and was founded in 2013.
Voyager's gene therapy platform is designed to deliver therapeutic genes directly to the brain, with the goal of treating diseases that are caused by genetic mutations or other genetic factors. The company's lead product candidate is VY-AADC, a gene therapy for Parkinson's disease that is currently in Phase 2 clinical trials.
Voyager also has programs in preclinical development for Huntington's disease, amyotrophic lateral sclerosis (ALS), and Friedreich's ataxia. The company has partnerships with several pharmaceutical companies, including AbbVie, Sanofi, and Neurocrine Biosciences.
Voyager's approach to gene therapy has the potential to revolutionize the treatment of neurological diseases, which are often difficult to treat with traditional medications. The company's innovative technology and strong partnerships make it a promising player in the biotech industry.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Voyager's gene therapy platform is designed to deliver therapeutic genes directly to the brain, with the goal of treating diseases that are caused by genetic mutations or other genetic factors. The company's lead product candidate is VY-AADC, a gene therapy for Parkinson's disease that is currently in Phase 2 clinical trials.
Voyager also has programs in preclinical development for Huntington's disease, amyotrophic lateral sclerosis (ALS), and Friedreich's ataxia. The company has partnerships with several pharmaceutical companies, including AbbVie, Sanofi, and Neurocrine Biosciences.
Voyager's approach to gene therapy has the potential to revolutionize the treatment of neurological diseases, which are often difficult to treat with traditional medications. The company's innovative technology and strong partnerships make it a promising player in the biotech industry.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!